P/B
19,4
Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
$8.5B
Market Cap • 9/14/2026
1989
(37 years)
Founded
1991
(35 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
9,8
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,7
EPS
—
Market Cap
Market Cap
8,5B
EV
8,1B
EV/Revenue
9,3
EV/EBITDA
-14,3
EV/EBIT
-13,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-3,1%
Total Yield
-3,1%
Payout
0%
Retained Earnings
-2,8B
Profitability
Gross Margin
98,2%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
105,8%
Capex/Revenue
7,4%
Capex/D&A
239,2%
Capex/OCF
-13%
SBC/OCF
—
% PPE
12,9%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
4,9%
CAGR Op. Income 5Y
21,5%
CAGR Net Income 5Y
0,1%
CAGR EPS 5Y
-2,5%
CAGR OCF 5Y
75,7%
Leverage
N.D./EBITDA
0,8
Debt/Equity
0%
Current Ratio
7,9
Quick Ratio
6,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!